日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study

奥莫替尼联合卡铂-培美曲塞对比奥莫替尼单药治疗EGFR和伴随肿瘤抑制基因的非小细胞肺癌(ACROSS2):一项开放标签、多中心、随机3期研究

Duan, Jian-Chun; Zhong, Jia; Sun, Bo-Yang; Zhao, Wen-Hua; Wu, Lin; Fei, Kai-Lun; Chu, Qian; Guo, Qi-Sen; Song, Qi-Bin; Yu, Yan; Zhu, Da-Xing; Liu, Xin-Yan; Zhao, Jun; Zhan, Zhi-Xiang; Li, Shi; Nie, Lei; Lin, Jie; Peng, Xiao-Dong; Zhong, Dian-Sheng; Zhou, Jin; Li, Li-Hua; Chen, Yun-Fang; Hu, Chen; Mok, Tony; Wang, Zhi-Jie; Wang, Jie

The consensus molecular subtypes of esophageal squamous cell carcinoma

食管鳞状细胞癌的共识分子亚型

Cui, Heyang; Zhu, Zhongxu; Xu, Enwei; Qi, Lin; Cheng, Yikun; Zhang, Yinghan; Zhang, Ling; Cheng, Matthew Yibo; Yang, Bin; Sun, Ruifang; Zhuang, Xiaofei; Xi, Yanfeng; Yan, Ting; Cheng, Caixia; Ding, Ning; Liu, Huijuan; Wang, Lu; Guo, Min; Guo, Dinghe; Zhang, Haoyu; Peng, Meilan; An, Zhekun; Weng, Yongjia; Wang, Fang; Liu, Meng; Xiong, Ruixin; Yin, Weihua; Song, Bin; Zhang, Weimin; Cheng, Xiaolong; Liu, Zhihua; Zhan, Qimin; Wang, Xin; Cui, Yongping

PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure

PRIME-HFrEF试验:一项针对心力衰竭的随机、双盲、多剂量脐带间充质干细胞治疗方案

Han, Wei; Jiao, Yuheng; Chen, Wei; Gong, Xin; Hu, Hao; Xin, Yuanfeng; Guan, Sibin; Zhao, Jun; Zhang, Qi; Yang, Bing; Pan, Jingwei; Wang, Haiyan; Lu, Qing; Chu, Shuguang; Cai, Dihui; Zheng, Liang; Jia, Wenwen; He, Zhiying; Yang, Huangtian; Sun, Yi Eve; Liu, Zhongmin

Signaling pathways and targeted interventions for precancers

癌前病变的信号通路和靶向干预

Yang, Jin; Wang, Shimeng; Li, Xin; Xu, Hongdan; Sun, Tongxu; Hu, Tao; Luo, Jingjing; Zhou, Hongmei

HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)

HDAC抑制剂tucidinostat和节拍式卡培他滨联合内分泌治疗用于CDK4/6抑制剂治疗后HR阳性HER2阴性晚期乳腺癌患者:一项多中心2期研究的临床结果和探索性循环肿瘤细胞和ctDNA生物标志物分析(SYSUCC-020试验)

Wu, Huai-Liang; Xia, Wen; Xu, Zhengyang; Zhou, Hanxing; Chen, Limin; Lu, Yongkui; Liu, Xinlan; Pang, Danmei; Liu, Yan; Lu, Qianyi; Xu, Fei; An, Xin; Huang, Jiajia; Jiang, Kuikui; Zhang, Jingmin; Cai, Yili; Hong, Ruoxi; Zheng, Qiufan; Wang, Shusen

Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance.

利用针对膜近端 AXL 的抗体对肿瘤微环境进行重编程,以克服免疫检查点阻断耐药性。

Yang Zuming, Cao Shuaishuai, Zhang Jiaen, Nie Xiaohua, Wang Zhimin, Yang Shaojun, Wang Jingshu, Sun Xin, Kuang Xueli, Huang Huiming, Wei Zifan, Duan Pengfei, Tang Mingwan, Zhang Liyu, Ren Zhenhua, Lan Xun, Fu Yang-Xin, Zhang Liguo, Zhang Xuyuan, Liang Yong

Exogenous Epstein-Barr virus nuclear antigen 1 induces ADAR1-driven tumor resistance against immunotherapy.

外源性 Epstein-Barr 病毒核抗原 1 诱导 ADAR1 驱动的肿瘤对免疫疗法产生耐药性。

Liu Changlin, Sun Zhiqiang, Li Chao, Zhou Yanqing, Gao Xuefeng, Zhong Yuping, Luo Xiaomin, Wang Chenci, Zhang Yuanbin, Ni Chuping, Peng Manli, Jian Weiquan, Yang Yinggui, Zhang Xuewen, Ren Yichang, Gong Xinqi, Zhao Min, Guo Xia, Cheng Chao, Chen Jianjun, Li Xin

Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials

IX因子-Padua AAV基因疗法治疗B型血友病:1/2期和3期试验

Xue, Feng; Ju, Mankai; Zhu, Tienan; Zhou, Zeping; Sun, Jing; Yang, Linhua; Yan, Zhenyu; Zhou, Hu; Du, Xin; Zheng, ChangCheng; Zheng, Jing; Wu, Xia; Du, Zengmin; Jiang, Wei; Yang, Caifeng; Xiao, Xiao; Liu, Wei; Yang, Renchi; Zhang, Lei

Towards fibre-like loss for photonic integration from violet to near-infrared

面向紫光到近红外波段光子集成的类光纤损耗

Chen, Hao-Jing; Colburn, Kellan; Liu, Peng; Yan, Hongrui; Hou, Hanfei; Ge, Jinhao; Liu, Jin-Yu; Lehan, Phineas; Ji, Qing-Xin; Yuan, Zhiquan; Bouwmeester, Dirk; Holmes, Christopher; Gates, James; Blauvelt, Henry; Vahala, Kerry

Insulin resistance prediction from wearables and routine blood biomarkers

利用可穿戴设备和常规血液生物标志物预测胰岛素抵抗

Metwally, Ahmed A; Heydari, A Ali; McDuff, Daniel; Solot, Alexandru; Esmaeilpour, Zeinab; Faranesh, Anthony Z; Zhou, Menglian; Narayanswamy, Girish; Xu, Maxwell A; Liu, Xin; Yang, Yuzhe; Savage, David B; Malhotra, Mark; Heneghan, Conor; Patel, Shwetak; Speed, Cathy; Prieto, Javier L